KEDPLASMA announces nationwide facility remodeling project
The initiative aims at enhancing the experience of its donors who stand at the beginning of a bridge between patients and their care
Kedrion attended the 75th Annual Bleeding Disorders Conference in the US
The company supported the Plasminogen Deficiency Foundation in a round-table for patients with Congenital Plasminogen Deficiency
Kedrion supports the IDF Research Grant Program for the second year
The Program encourages and supports patient-oriented research on Primary Immunodeficiencies
Kedrion confirms its commitment against Rabies infections in the US
Distribution agreement with Kamada for KEDRAB® extended until March 2026
Kedrion’s global portfolio expands to China
BPL’s Human Albumin is our first ever product approved in the Chinese market
Kedrion awarded national tender for Portuguese plasma manufacturing
First shipments of plasma from Porto and Lisbon were received in the beginning of February
Kedrion strengthens its network of plasma collection centers
Five centers acquired in the Czech Republic
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Kedrion Biopharma Recognized for innovation in Treating Rare Disease
Prestigious recognition presented for the first ever treatment for Plasminogen Deficiency
World Hemophilia Day: Kedrion’s commitment
Guaranteeing equitable access to treatment is the central theme of the 2022 edition
